Kane Biotech Inc.
KNE.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 17.99% | 33.48% | 56.78% | 1,133.19% | -16.59% |
| Total Depreciation and Amortization | -16.96% | 5.83% | -23.77% | -10.59% | -10.49% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -10.45% | -25.52% | -80.63% | -1,172.22% | 3,176.47% |
| Change in Net Operating Assets | -186.70% | -8.58% | -74.78% | -528.40% | -22.09% |
| Cash from Operations | -5.34% | 48.35% | 26.03% | -656.99% | -2.92% |
| Capital Expenditure | -152.63% | 31.91% | -76.19% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -102.43% | -104.34% | 88.84% | -759.73% | 9,818.48% |
| Cash from Investing | -103.50% | -96.23% | 74.59% | 15,224.94% | 9,777.17% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 19.89% | -1.11% | -1.05% | -3,951.02% | -657.25% |
| Issuance of Common Stock | -- | -- | -40.12% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 93.80% | -103.27% | 63.59% | -8,860.13% | -63.14% |
| Cash from Financing | 400.57% | -18.24% | -93.50% | -4,332.29% | -146.95% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 168.49% | -167.93% | -195.95% | -536.40% | -61.48% |